Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
Status:
Completed
Trial end date:
2014-05-14
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best way to give sunitinib malate in
treating patients with unresectable or metastatic kidney cancer or other advanced solid
tumors. Sunitinib malate may stop the growth of tumor cells by blocking blood flow to the
tumor and by blocking some of the enzymes needed for cell growth.